Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company, today announced a stock repurchase program under which the company may purchase up to $10.0 million of its common stock through December 31, 2011. Since December 2009, Maxygen has repurchased approximately 10.0 million shares of its common stock at an aggregate cost of approximately $54.1 million.
